Voronoi Presents 'VRN11' Clinical Results at ESMO… "20% of Brain Metastasis Patients Achieve Complete Remission"
Predicted impact: Medium
Clinical data for a lead drug with strong response; meaningful for a biotech of this size.
Voronoi보로노이
310210 · KOSDAQ · ₩310210 · 보로노이
₩121,100▲ ₩2,300 (1.94%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −41.64%
- Market cap
- ₩2.3T
- Enterprise value
- ₩2.3T
- P/E
- —
- P/B
- 32.6×
- Dividend yield
- 0.0%
- ROE
- −99.9%
- Net margin
- −1,661.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−67.7% from the high
₩97,500Today: ₩118,100 – ₩126,500₩375,500
Returns
- 1W−11.5%
- 1M−12.1%
- 3M+13.3%
- 6M−59.1%
- YTD−44.3%
- 1Y−41.6%
- Volume today
- 65,032
- 0.9× the 20-day average
- Traded today
- ₩7.9B
- Listed shares
- 18,616,563
- EPS (12 months)
- −₩3,714
- Earnings yield −3.1%
AI research · InitiationVoronoi: Deep Losses and Minimal Revenue Meet a Share Price Well Below Its 52-Week HighThe filed data shows a company with widening losses, little revenue and a limited cash balance, yet with a market value of about ₩2.3T.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Positive trial headline reported by a news outlet. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-17.8% over the last month; the price is below its 20-day average.
- News impactSome7 news items and filings in two weeks; 0 rated high impact, 4 medium.
- StreetSteady1 brokers, average target 272% from the price; last 30 days: 0 raised, 0 cut.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 28: buy ₩3.7B at the close (40.0% of 20-day average trading value)
On its 34 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 18.6% of trading value and pointed the same way 28 of 34 times.
- 2× KODEX KOSDAQ150 Leverage ₩3.3B
- -1× KODEX KOSDAQ150 Futures Inverse ₩187M
- 2× TIGER KOSDAQ150 Leverage ₩170M
- 2× RISE KOSDAQ150 Futures Leverage ₩32M
- -1× TIGER KOSDAQ150 Futures Inverse ₩6.1M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.8%
- KODEX KOSDAQ150 Leverage2×0.8%
- TIGER KOSDAQ1500.8%
- RISE KOSDAQ1500.8%
- TIGER KOSDAQ150 Leverage2×0.8%
- ACE KOSDAQ 1500.8%
- KIWOOM KOSDAQ1500.8%
- SOL KOSDAQ1500.8%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 120,100
Basis −0.83% · implied rate −20.2%
Open interest 17,887 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Voronoi stock overview
Voronoi (보로노이, KRX: 310210) is listed on KOSDAQ, in the Biotech & Pharma sector. Voronoi is a Korean drug discovery company that develops kinase-targeted precision therapies, mainly anticancer drugs for lung cancer and breast cancer, with a focus on early-stage clinical development (Phase 1 to 2). Its shares closed at ₩121,100 on Oct 28, 2026, up 1.94% on the day, giving it a market value of ₩2.3T.
Key facts
- Market cap
- ₩2.3T
- Sector
- Biotech & Pharma
- Latest price change
- +1.94%
- As of
- Oct 28, 2026
- Main business
- Voronoi is a Korean drug discovery company that develops kinase-targeted precision therapies, mainly anticancer drugs for lung cancer and breast cancer, with a focus on early-stage clinical development (Phase 1 to 2).
Quick answers about Voronoi
- What does Voronoi do?
- Voronoi is a Korean drug discovery company that develops kinase-targeted precision therapies, mainly anticancer drugs for lung cancer and breast cancer, with a focus on early-stage clinical development (Phase 1 to 2). The company uses its in-house medicinal chemistry, biology, animal testing and AI research facilities to design candidate drugs, run early clinical trials, and then license them out to global pharmaceutical companies. Its proprietary VORONOMICS platform combines wet-lab experiments with artificial intelligence to improve drug selectivity and brain penetration, and it has licensed a lung cancer treatment to ORIC Pharmaceuticals, a Nasdaq-listed company in the United States.
- What is the market cap of Voronoi?
- The market capitalisation of Voronoi was ₩2.3T at the close on Oct 28, 2026.
- What is the analyst target price for Voronoi?
- The average target price of 1 broker covering Voronoi is ₩450,000 (range ₩450,000 to ₩450,000), 271.6% above versus the latest price, based on each broker's latest public report within six months.
- Who are the largest shareholders of Voronoi?
- According to the latest official filings, the largest reported holders are Kim Hyun-tae (40.57%, as of Aug 31, 2026); National Pension Service (2.78%, as of Dec 31, 2025); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.91%, as of Jul 31, 2026).
- When is the next earnings report from Voronoi?
- Korean companies rarely announce results dates in advance. Based on when Voronoi filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Voronoi?
- Yes. The National Pension Service held 2.78% of Voronoi shares as of Dec 31, 2025.
Company profile
Voronoi is a Korean drug discovery company that develops kinase-targeted precision therapies, mainly anticancer drugs for lung cancer and breast cancer, with a focus on early-stage clinical development (Phase 1 to 2). The company uses its in-house medicinal chemistry, biology, animal testing and AI research facilities to design candidate drugs, run early clinical trials, and then license them out to global pharmaceutical companies. Its proprietary VORONOMICS platform combines wet-lab experiments with artificial intelligence to improve drug selectivity and brain penetration, and it has licensed a lung cancer treatment to ORIC Pharmaceuticals, a Nasdaq-listed company in the United States.
Written by AI from the company's latest annual report.
- Korean name
- 보로노이
- Sector
- Biotech & Pharma
- CEO
- 김현태
- Founded
- Feb 2015
- Listed
- Jun 2022
- Listed shares
- 18,616,563
- Fiscal year ends
- Month 12
- Website
- voronoi.io
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Voronoi Announces Phase 1 Results for Targeted Anticancer Drug 'VRN10'…"Encouraging Results"
Predicted impact: Low
Phase 1 clinical trial results for a drug candidate; no revenue size or financial impact given.
[Exclusive] Voronoi pushes ahead with ₩80B CB issuance… signs of overbooking despite weak share price
Predicted impact: Low
₩80B convertible bond is about 3% of market value; overbooking signals demand, below the ~5% threshold.
Recent filings
See all- Amended: Major management matter relevant to investorsOct 20, 2026
- Investor relations (IR) eventOct 13, 2026
- Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)Oct 8, 2026
- Amended: Half-year report (Jun 2026)Oct 2, 2026
- Amended: Major management matter relevant to investorsSep 18, 2026
Titles in Korean until English translations are added.
Also known as: Voronoi / 보로노이 / 310210 / KRX:310210
Source: KRX statistical information